Welcome to our dedicated page for Guardion Health Sciences news (Ticker: GHSI), a resource for investors and traders seeking the latest updates and insights on Guardion Health Sciences stock.
Guardion Health Sciences Inc (GHSI) delivers innovative medical foods and nutritional solutions targeting age-related health challenges, with particular focus on ocular health. This news hub provides investors and healthcare professionals with verified updates about the company's scientific advancements, regulatory milestones, and market developments.
Access timely reports on clinical research outcomes, product innovations, and strategic partnerships that demonstrate GHSI's commitment to evidence-based nutritional science. Our curated collection includes earnings announcements, FDA updates, and expert insights from the company's scientific advisory board.
Key updates cover three core areas: clinical research developments in macular health support, regulatory progress for medical food formulations, and strategic initiatives enhancing distribution networks. Bookmark this page to stay informed about GHSI's role in advancing condition-specific nutrition through pharmaceutical-grade research methodologies.
Guardion Health Sciences (GHSI) reported Q3 2022 revenues of $2.66 million, a 15% decline from $3.15 million in Q3 2021, primarily due to reduced sales of its Viactiv product line, which accounted for 96% of total revenues. Gross profit decreased by 22% to $1.09 million, leading to a gross margin of 40.9%. The company reported an operating loss of $1.74 million, an improvement from the previous year's loss of $3.02 million. Also, GHSI engaged Roth Capital Partners for a strategic review to explore opportunities for maximizing stockholder value.
Guardion Health Sciences (GHSI) announced interim results from a clinical study showing that its new Viactiv Omega Boost Gel Bites increased Omega-3 levels by 51% in just 4 weeks. The gel bites contain 1,200 mg of Omega-3s (DHA and EPA) and have a chewable format, providing a more palatable alternative to traditional fish oil pills, with no sugar or fishy aftertaste. CEO Bret Scholtes emphasized that despite a premium price, the product offers value due to its proven effectiveness. Viactiv products are available for purchase online.
Guardion Health Sciences (GHSI) reported its highest quarterly revenue of approximately $3.275 million for Q2 2022, a 37.3% increase from $2.38 million in Q1. The Viactiv® product line, acquired in June 2021, significantly contributed to the revenue growth. Gross profit was $1.40 million, with a gross margin of 42.7%, impacted by a $109,363 impairment charge for outdated packaging. The company reduced its operational loss to $(1.71 million) from $(4.54 million) year-over-year. Despite supply chain issues, Guardion remains optimistic about future growth and plans to expand its product offerings.
Guardion Health Sciences (NASDAQ: GHSI) announced that ISS recommends stockholders vote in favor of two key proposals at the Annual Meeting on June 16, 2022. Proposal 3 seeks to amend the 2018 Equity Incentive Plan to allow sufficient stock-based compensation until 2024. Proposal 4 requests authorization for a reverse stock split to avoid potential delisting from Nasdaq for not meeting the $1 minimum bid requirement, which could adversely affect liquidity. Stockholders of record as of April 18, 2022, are eligible to vote.
Guardion Health Sciences (Nasdaq: GHSI) has entered into a partnership with OmegaQuant Laboratories to enhance its product testing capabilities. OmegaQuant, a CLIA-certified lab in South Dakota, provides comprehensive fatty acid analysis, including Omega-3 Index testing. This collaboration will support Guardion's research projects to evaluate product efficacy, particularly for its new Omega Boost 1,200 mg Omega-3 Gel Bites. Guardion's CEO, Bret Scholtes, sees this relationship as a significant opportunity for scientific advancement in clinical nutrition.
Guardion Health Sciences, Inc. (Nasdaq: GHSI) announced the launch of Viactiv Omega Boost 1,200 mg Omega-3 Gel Bites on Amazon.com, marking a significant retail expansion for the product. The gel bites offer ten times more Omega-3 than leading fish oil gummies without the typical fishy taste and sugar. These Gel Bites are designed to support cardiovascular, brain, joint, and eye health. CEO Bret Scholtes emphasized the importance of this milestone in making the product more accessible to consumers.
Guardion Health Sciences, Inc. (GHSI) reported a significant increase in revenues for the quarter ending March 31, 2022, achieving approximately $2.4 million, up from $233,297 a year earlier. The acquisition of the Viactiv® brand has positively transformed the company's operations. Despite a net loss per share improvement to $(0.07) from $(0.13), operational losses remain substantial at $(2.62 million). The company possesses $16.8 million in cash, enabling future growth initiatives, including the launch of new products like the Omega Boost Gel Bites.
Guardion Health Sciences announced that CEO Bret Scholtes will present at the Planet MicroCap Showcase 2022 from May 3-5, 2022, in Las Vegas. The presentation is scheduled for May 4 at 5:00pm Pacific Time. Attendees can access the event via a webcast link. Guardion Health Sciences focuses on clinically supported nutrition and supplements aimed at healthcare professionals and consumers. The company continues to strengthen its position in the clinical nutrition market through scientific expertise and innovation.
Guardion Health Sciences, Inc. (GHSI) has launched Viactiv® Omega Boost gel bites, now available for purchase directly from its website. These gel bites offer 1,200 mg of Omega-3, providing enhanced support for cardiovascular, brain, joint, and eye health. The product boasts ten times more Omega-3s than leading fish oil gummies, without the fishy taste or added sugars. This launch signifies a critical step in Guardion's product development process, aimed at efficiently meeting consumer nutritional needs.
Guardion Health Sciences (GHSI) reported strong financial growth for 2021, with revenues reaching $7.2 million, up 283% from 2020, largely due to the acquisition of the Viactiv brand. Viactiv contributed approximately $6.5 million to overall revenues. However, the company faced an operating loss of $24.7 million, significantly impacted by acquisition costs and a goodwill impairment charge. Despite challenges like inventory management and supply chain issues, demand remains strong. Cash and short-term investments stood at $9.1 million by the year's end.
